Current research for a vaccine against Lassa hemorrhagic fever virus

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Lassa fever 3 infectiousdiseases
diarrhea 1 infectiousdiseases
ribavirin 3 infectiousdiseasesdrugs
vaccinia 7 infectiousdiseases
yellow fever 4 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
ribavirin 4133 therapeutics for the treatment or prevention of LASV with the questionable exception of the off-label use of ribavirin .[6] Additionally, historical imported cases of LASV infection and human-to-human transmission warrant
ribavirin 15551 electroporation.[42]–[44] Additionally, therapeutics have been developed that include the preclinical testing of ribavirin and favipiravir. Currently, the best therapeutic strategy against LASV remains favipiravir, which can
ribavirin 28153 listed relative to infection. *Following symptom onset.Abbreviations: NHPs, non-human primates; Rib, ribavirin ; Fav, favipiravir; VSV-LASV, vesicular stomatitis virus-Lassa virus.Table 1Animal testing of replication-competent
Select Disease Character Offset Disease Term Instance
Lassa fever 570 8/2018AbstractLassa virus (LASV) is a rodent-borne arenavirus endemic to several West African countries that causes Lassa fever (LF). LF is typically mild but it can cause severe disease characterized by hemorrhagic fever and multi-organ
Lassa fever 1940 vaccines for LASV critical.IntroductionNigeria is currently struggling with a severe reoccurrence of Lassa fever (LF), with confirmed cases in over half of the country (18 States).[1] The World Health Organization
Lassa fever 15120 neutralizing titers and may be feasible for protection against LASV.Preclinical vaccine candidates for Lassa fever There has been considerable progress made in the development of preclinical vaccine candidates for the
diarrhea 3349 incubation period of LF is typically 1–3 weeks with accompanying headache, fever, muscle/joint pain, diarrhea , vomiting, elevated liver enzymes (AST and ALT), and hematocrit. The signs of pathogenesis can vary
vaccinia 12487 immunity is important for protection against LF. Strong T-cell responses against GP1 and GP2 induced by a vaccinia -vectored LASV vaccine were protective against LASV challenge.[31] In addition, strong activation and
vaccinia 16118 for LASV prevention have been based on replication-competent vaccine modalities (Table 1).Recombinant vaccinia virus vaccine platformIn 1987, the first successful vaccine directed against LASV was described. A recombinant
vaccinia 16238 vaccine platformIn 1987, the first successful vaccine directed against LASV was described. A recombinant vaccinia virus (Lister strain) was engineered to express the NP from LASV and given to outbred Hartley guinea
vaccinia 16968 guinea pig-adapted version of Josiah confirmed the protective efficacy of various recombinant strains of vaccinia expressing either LASV NP or GPC with 94% and 79% protection, respectively.[47] In contrast to the initial
vaccinia 17084 expressing either LASV NP or GPC with 94% and 79% protection, respectively.[47] In contrast to the initial vaccinia experiments, most animals including the recombinant vaccine vaccinated animals showed some signs of
vaccinia 17322 acute viremia that was 10-fold less than control animals. Interestingly, a combination of NP and GPC vaccinia viruses led to a poorer outcome with only 58% protection. A set of secondary comprehensive studies was
vaccinia 17502 secondary comprehensive studies was undertaken in rhesus and cynomolgus macaques to test the individual vaccinia vaccines expressing GP1, GP2, and NP.[31] Ninety percent of animals that received all three proteins
yellow fever 19842 recombinant virus as well as safety in HIV-infected individuals within LASV endemic regions.[32]Recombinant yellow fever vaccine platform, YF17DAnother recombinant vaccine developed by the same research group[53] makes use
yellow fever 19964 platform, YF17DAnother recombinant vaccine developed by the same research group[53] makes use of the yellow fever 17D (YF17D) vaccine, which is one of the safest and most effective vaccines ever developed. The YF17D
yellow fever 21036 is a safe vaccine, more development is currently needed to achieve an efficacious vaccine for both yellow fever and LASV.Recombinant vesicular stomatitis virus vaccine platform, VSVDespite the considerable list of
yellow fever 28752 LASV, Lassa virus; NHPs, non-human primates; NP, nucleoprotein; GPC, glycoprotein precursor; YFV17D, yellow fever 17D; VSV, vesicular stomatitis virus

You must be authorized to submit a review.